Skip to content

Clinical trials

Observational Cardiovascular Diseases trials in the United Kingdom

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Cardiovascular Diseases Phase: Observational Country / region: United Kingdom Clear all

120 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20081
20093
20103
20111
20127
20132
20143
20156
20168
20179
20189
20197
202015
20216
20226
20239
202410
20258
20265

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed43
Unknown status29
Recruiting24
Active, not recruiting11
Not yet recruiting6
Terminated4
Enrolling by invitation3

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
University of Leicester9
University College, London8
Imperial College London7
Cambridge University Hospitals NHS Foundation Trust6
NHS Greater Glasgow and Clyde5
University of Edinburgh4
University of Manchester4
Bayer3
King's College Hospital NHS Trust3
Queen Mary University of London3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Cardiovascular Diseases120
Heart Diseases14
Coronary Artery Disease13
Hypertension11
Diabetes Mellitus10
Renal Insufficiency, Chronic9
Atherosclerosis8
Coronary Disease8
Heart Failure7
Vascular Diseases7

Trials

Showing 1 to 25 of 120. Each trial links to its page on Pharma Observatory.

20 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.